title: Optimizing immunomodulatory therapy for MS patients: an integrated management model.
authors.forename: Douglas
authors.initials: D
authors.lastname: Jeffery
authors.forename: Khurram
authors.initials: K
authors.lastname: Bashir
authors.forename: Linda
authors.initials: L
authors.lastname: Buchwald
authors.forename: Patricia
authors.initials: P
authors.lastname: Coyle
authors.forename: Mark
authors.initials: M
authors.lastname: Freedman
authors.forename: Clyde
authors.initials: C
authors.lastname: Markowitz
authors.forename: Kottil
authors.initials: K
authors.lastname: Rammohan
authors.forename: Tony
authors.initials: T
authors.lastname: Reder
authors.forename: Mo
authors.initials: M
authors.lastname: Sharief
authors.forename: Jerry
authors.initials: J
authors.lastname: Wolinsky
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D004358:Drug Therapy / Q000592:standards; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a